Citations 1
Microtubule Acetylation Regulates the Malignant Phenotype of Glioblastoma and is a Promising Therapeutic Target
Dovas, Athanassios, Bhattacharya, Santanu, Kulkarni, Tanmay, Amini, Misha, Haddock, Ashley, Nagaiah, Naveen KH, Mukhopadhyay, Debrabrata, Suarez-Meade, Paola, Quinones-Hinojosa, Alfredo, Canoll, Peter, Kenchappa, Rajappa, Rosenfeld, Steven S. , Rosenfeld, Steven S , Zarco, Natanael , Bhattacharya, Santanu , Kulkarni, Tanmay, Liu, Yi , Haddock, Ashley , Nagaiah, Naveen K H, Suárez-Meade, Paola , Quiñones‐Hinojosa, Alfredo , Miller, Courtney A. , Kamenecka, Theodore M. , Canoll, Peter, Kenchappa, Rajappa S.
No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
ABSTRACT Glioblastoma (GBM) is universally lethal despite decades of research to find effective treatments. This highlights the need to identify druggable targets essential for sustaining the malignant phenotype but dispensable for normal tissue. We propose that the enzyme α-tubulin acetyl transferase ( ATAT1 ) meets these criteria. ATAT1 acetylates α-tubulin at lysine 40, which increases microtubule stability and promotes microtubule-based transport. While ATAT1 knockout mice have only a very mild phenotype, ATAT1 suppression in GBM has multiple therapeutic effects by reducing tumor invasion, proliferation, and therapeutic resistance. These translate not only into improved survival with ATAT1 targeting by itself, but also into synergy when ATAT1 deletion is combined with FDA approved therapies. This study strongly supports our conclusion that ATAT1 is a promising therapeutic target in GBM.